CV Risk Reduction in Diabetes (SGLT2i/GLP-1 RA and CVD) - June 3, 2020
by CHEP+
Date and time
Description
Upcoming CPD Sessions
CV Risk Reduction in Diabetes (SGLT2 inhibitors/GLP-1 Receptor Agonists in Patients with DM and CVD)
June 3, 2020 • 7-9PM Eastern Time
Speaker Dr. Richard Choi, moderator Dr. Sheldon Tobe
Upon completion of this activity, participants should be able to:
- Describe the patient who should be treated with an SGLT2i or GLP-1 RA.
- Explain the rational for this treatment and the potential benefits.
- Describe the steps for initiating and monitoring therapy for patients with diabetes.
Accredited for 3 credits per hour, total of maximum 6 credits.
FAQs
• How can I contact the organizer with any questions?
To contact the organizer, email: Diane Hua-Stewart at diane.hua@sunnybrook.ca.
• To learn more:
Please visit the event website: https://www.cchangeguidelines.com/
